A common challenge for investors is finding companies that not only have good basic business qualities but also show positive price movement. One way to do this is by joining technical and fundamental study, looking for stocks that are increasing quickly while also showing good technical breakout shapes. This method tries to find companies where better financial and profit conditions are being seen by the market, possibly marking the start of a continued rise. Apellis Pharmaceuticals Inc (NASDAQ:APLS) recently appeared from this kind of search, needing a more detailed view of both its increase story and its present chart situation.
A Look at Good Increase Basics
The basic search for this plan focuses first on companies showing good increase, which is a key part of increase investing. The aim is to find businesses growing their profits and sales at a pace much quicker than similar companies, as this frequently comes before major price gains. According to its fundamental analysis report, Apellis gets a Growth Rating of 7 out of 10, pointing to good increase measures.
Important increase points are:
- Fast Profit Growth: The company's Earnings Per Share (EPS) grew by a notable 108.97% over the last year, a clear sign of quickening profit.
- Steady Sales Growth: Sales have risen by 28.46% in the last year and have averaged close to 32% yearly growth over recent years, showing good business action.
- Positive Coming View: Experts think this movement will keep going, with EPS forecast to grow by about 86% each year in the near future.
This increase is being pushed by the business launch of its main therapy, SYFOVRE®, the first and only accepted treatment for geographic atrophy, a main reason for blindness. The company's skill in turning its new science into quickly growing sales is a standard feature of a good increase stock.
Helping Basics: Profit and Financial Condition
While increase is most important, lasting growth needs a firm working and financial base. The search rules also ask for "acceptable" ratings in profit and financial condition to remove companies that are growing in an unstable way or have poor financial footing.
Apellis's basics in these areas are helpful:
- Profit Becoming Positive: The company gets a Profit Rating of 6. After years of spending, it has lately reached positive profits and operating cash flow. Its profit margins are especially good, with a Gross Margin near 90% and an Operating Margin that is better than 89% of its biotech industry friends.
- Sufficient Financial Condition: With a Health Rating of 5, the company's money position is seen as medium. It keeps a good Current Ratio of 3.14, pointing to acceptable short-term cash to pay for operations. But, investors should see the company's use of debt and a high Debt-to-Free-Cash-Flow ratio, which are normal in business-stage biotech companies spending much on launch actions.
A Technical Situation Showing Movement
The second part of this plan includes finding a positive technical shape. A stock with good basics can stay still for a while; a technical breakout can show that the market is starting to value that basic gain. Apellis's technical analysis report gives a top rating of 10, with a specific Setup Rating of 7, pointing to a good chart arrangement.
The technical view is positive:
- Strong Upward Movement: Both the long and short-term directions are clearly positive. The stock is trading well over its important moving averages (20, 50, 100, and 200-day SMAs), which are all moving upward.
- Market Beating Performance: APLS has been a top performer, doing better than 96% of all stocks and 84% of its biotech friends over the last year. It is now trading at a new 52-week high.
- Narrowing Near a Price Ceiling: After a large rise, the stock has been moving in a band between about $40.64 and $40.90. This lessening of movement near an important price ceiling often comes before a clear move. The technical report notes a clear price ceiling zone just over the present price at $40.88, with a price floor zone under near $40.86, making a set risk/reward situation for a possible breakout.
Why This Pairing is Important
The link between the fundamental and technical reports is what makes this search method interesting. The good Growth Rating confirms Apellis is doing its business plan and growing quickly, a must for an increase investment. The acceptable Profit and Health Ratings give confidence that this increase is starting to show in final profits and is helped by a workable financial setup. Lastly, the high Technical and Setup Ratings suggest this basic story is getting wide market notice, with the stock's price action narrowing in a way that often comes before the next upward step.
For investors using this joined plan, Apellis shows a case where the number-based increase story is being checked by observed market movement.
Interested in finding other stocks that match this picture of good increase joined with good technical situations? You can do the same search using our stock screener.
Disclaimer: This article is for information only and does not make financial advice, a suggestion, or a deal or request to buy or sell any securities. The study is based on data and reports from ChartMill.com. Investing has risk, including the possible loss of the main amount. You should do your own study and talk with a qualified financial advisor before making any investment choices. Past results do not show future outcomes.